The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
The oral PARP inhibitor niraparib yielded significantly improved progression-free survival for women with platinum-sensitive, recurrent ovarian cancer in a phase III trial.
Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations.
For some time, genetic testing has been predictive and prognostic. It is now assuming a therapeutic role as well. An example is the targeting of breast cancer patients with BRCA mutations for treatment with PARP inhibitors.
The FDA issued a recommendation against the use of any currently available screening tests for ovarian cancer.
Ovarian cancer mortality rates declined significantly in several parts of the world from 2002 to 2012, according to a new study. Among the main reasons for the decline is the use of oral contraceptives, particular in the United States and European Union.
This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.
Over a 10-year period, the use of neoadjuvant chemotherapy increased significantly in women with advanced ovarian cancer, according to a new observational study.
In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.
A study found that follicle-stimulating hormone receptors are expressed in many ovarian tumors, and not in normal ovarian tissue, thus representing a promising therapeutic target.